TransCode Therapeutics (NASDAQ:RNAZ) Upgraded at Wall Street Zen

TransCode Therapeutics (NASDAQ:RNAZ) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Friday.

Separately, HC Wainwright dropped their price target on TransCode Therapeutics from $560.00 to $280.00 and set a “buy” rating for the company in a research note on Wednesday, April 16th.

TransCode Therapeutics Stock Performance

Shares of NASDAQ RNAZ opened at $9.94 on Friday. The firm’s 50 day moving average price is $7.88 and its 200 day moving average price is $62.09. TransCode Therapeutics has a 1 year low of $6.15 and a 1 year high of $822.36.

TransCode Therapeutics (NASDAQ:RNAZ) last posted its quarterly earnings results on Wednesday, May 21st. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.00) by $1.40. On average, equities research analysts forecast that TransCode Therapeutics will post -4.76 earnings per share for the current fiscal year.

Institutional Trading of TransCode Therapeutics

An institutional investor recently bought a new position in TransCode Therapeutics stock. Warberg Asset Management LLC bought a new stake in TransCode Therapeutics Inc. (NASDAQ:RNAZ) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $25,000. Warberg Asset Management LLC owned approximately 0.21% of TransCode Therapeutics as of its most recent filing with the Securities & Exchange Commission.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.